评估黑人与亚洲男性中PI-RADS病灶及临床显著前列腺癌:PREVENT随机临床试验二次分析
该研究为PREVENT试验的二次分析,比较了自我认同为黑人和亚洲男性与白人男性在PI-RADS 3-5病灶下的前列腺癌检出率。结果显示,黑人男性在PI-RADS 3/4病灶中临床显著前列腺癌的比值比更高,而亚洲男性在PI-RADS 3病灶中所有癌症检出均为阴性,提示PI-RADS评分在非白人男性中可能需要差异化解读。
要点
- 黑人男性PI-RADS 3/4病灶的临床显著前列腺癌比值比白人高20%。
- 亚洲男性PI-RADS 3病灶中总体和临床显著前列腺癌检出率均为0%。
- PI-RADS评分在非白人男性中可能需要差异化解读。
核心结论
- 黑人男性PI-RADS 3/4病灶的临床显著前列腺癌比值比白人男性高20%,而亚洲男性所有PI-RADS 3病灶均为阴性。
研究设计与样本
- PREVENT多机构随机临床试验的二次分析,纳入665/752例PI-RADS 3-5病灶患者,其中黑人88例(13%),亚洲人36例(6%)。
主要发现
- 黑人男性诊断时更年轻,PI-RADS 3病灶中总体癌检出率70% vs 白人43%(P=0.004),临床显著癌60% vs 27%(P=0.003)。
- 亚洲男性PI-RADS 3病灶中总体癌检出率0% vs 白人47%(P=0.004),临床显著癌0% vs 27%(P=0.003)。
- 多变量回归中,黑人男性PI-RADS 3/4病灶总体癌OR 1.17(P=0.009),临床显著癌OR 1.20(P=0.004)。
- 亚洲男性总体癌OR 0.79(P=0.01),临床显著癌OR 0.94(P=0.5)。
临床怎么用
- 临床解读PI-RADS评分时应考虑种族差异,对黑人男性PI-RADS 3/4病灶保持较高警惕。
- 对亚洲男性PI-RADS 3病灶可结合其他指标审慎评估,避免过度活检。
局限性
- 本研究为二次分析,黑人(88例)和亚洲人(36例)样本量较小,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Non-White patients are poorly represented in prostate cancer trials. MRI PI-RADS scoring was developed in primarily White populations, but prostate cancer differs in non-White men. We aimed to explore differences in PI-RADS calibration for Asian and Black men. MATERIALS AND METHODS: This is a secondary analysis of PREVENT, a multi-institutional study of infection rates for transrectal vs. transperineal biopsy. We compared cancer detection for self-identifying Asian and Black men. We compared detection rates on a per-person basis, stratified by index PI-RADS lesion, to White men, using Fisher's exact and logistic regression. RESULTS: Of 665/752 trial patients with PI-RADS 3-5 lesions, 88 (13%) were Black and 36 (6%) were Asian. Black men were younger at diagnosis with increased rates of overall (70% vs. 43%%, P = 0.004) and clinically significant prostate cancer (60% vs. 27%, P = 0.003) and Asian men had decreased rates of overall (0% vs. 47%, P = 0.004) and clinically significant prostate cancer (0% vs. 27%, P = 0.003) in PI-RADS 3 lesions compared to White men. On multivariable regression, Black men with PI-RADS 3/4 lesions had higher odds of overall (OR 1.17, P = 0.009) and clinically significant prostate cancer (OR 1.20, P = 0.004) and Asian men had lower odds of overall (OR 0.79, P = 0.01) but not clinically significant prostate cancer (OR 0.94, P = 0.5). CONCLUSIONS: Black men with PI-RADS 3/4 lesions had 20% higher odds of clinically significant prostate cancer than White men while all PI-RADS 3 lesions in Asian men were negative. These findings suggest PI-RADS may require differential interpretation when assessing prostate cancer risk in non-White men. TRIAL REGISTRATION: Registered at ClinicalTrials.gov ( NCT04843566 , https://clinicaltrials.gov/study/NCT04843566 ).
引用
- Driscoll CB, Handa N, Huang MM, et al. Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis. Prostate Cancer Prostatic Dis. 2025. PMID: 41298852. doi:10.1038/s41391-025-01057-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。